Lehrstuhl für Innere Medizin III

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study (2017) Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, et al. Journal article Reply to: Osteoporosis: An Independent Determinant of Bone Erosions in Rheumatoid Arthritis? (2017) Simon D, Simon C, Kleyer A, Schett G Journal article, Letter Unilateral plantar erythema nodosum in sarcoidosis (2017) Hueber A, Schett G, Manger B Journal article Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis (2017) Lauder SN, Allen-Redpath K, Slatter DA, Aldrovandi M, O'Connor A, Farewell D, Percy CL, et al. Journal article Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis (2017) Fischer S, Rath T, Geppert CI, Manger B, Schett G, Neurath M, Atreya R Journal article T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients (2016) Mummert C, Hofmann C, Hueckelhoven AG, Bergmann S, Mueller-Schmucker SM, Harrer EG, Dörrie J, et al. Journal article Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells (2016) Magorivska I, Munoz Becerra L, Janko C, Dumych T, Rech J, Schett G, Nimmerjahn F, et al. Journal article Type 2 Innate Lymphoid Cells - Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis (2016) Weber S, Wohlfahrt T, Rauber S, Luber M, Englbrecht M, Dees C, Beyer C, et al. Conference contribution THE INVOLVEMENT OF THE LONG NONCODING H19X IN TGF beta SIGNALING AND ITS PROFIBROTIC EFFECTS IN SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES (2016) Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Dobrota R, Brock M, Kurreeman F, et al. Conference contribution THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY (2016) Distler O, Maurer B, Vettori S, Blumhardt S, Frey D, Distler A, Beyer C, Distler J Conference contribution